MilliporeSigma To Become First Provider To Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada-based Life Science business of Merck KGaA, Darmstadt, Germany, has achieved a significant milestone as the world's first Contract Testing, Development, and Manufacturing Organization (CTDMO) to offer comprehensive, integrated services covering all critical phases of mRNA development, manufacturing, and commercialization. This achievement coincides with the inauguration of two state-of-the-art GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany, representing a €28 million investment and the creation of 75 new jobs.
MilliporeSigma's commitment to advancing mRNA technologies is underpinned by an ongoing €1 billion investment and strategic acquisitions like AmpTec and Exelead. The newly opened facilities enhance the company's capacity to offer mRNA services across all scales, from pre-clinical to commercial, with a focus on analytical development and biosafety testing tailored specifically for mRNA technologies. Moreover, the company provides differentiated PCR-based technology to ensure the production of high-quality mRNA for clinical and commercial applications, simplifying processes and accelerating time-to-market.
Since the 1990s, Merck KGaA's Life Science business has collaborated with researchers, providing critical components and raw materials essential for mRNA research. Leveraging its unique blend of mRNA expertise, cutting-edge technologies, regulatory knowledge, and diverse product portfolios, the company streamlines mRNA manufacturing and testing.
In addition to mRNA services, MilliporeSigma offers a range of capabilities, including monoclonal antibodies, recombinant proteins, viral vectors, small molecules, high-potent active pharmaceutical ingredients (HPAPI), and antibody-drug conjugates (ADCs), along with integrated analytical development, biosafety testing, and product characterization through its Millipore® CTDMO Services.
These services are part of the Life Science Services business unit, a key driver alongside the Process Solutions business in Merck KGaA, Darmstadt, Germany's "Big 3" growth strategy. The company's goal is to increase Group sales to approximately €25 billion by 2025, with approximately 80% of this growth expected to come from the "Big 3" growth drivers.
With a global presence, over 28,000 employees, and more than 55 manufacturing and testing sites, MilliporeSigma plays a pivotal role in scientific discovery, biomanufacturing, and testing services across healthcare, life science, and electronics sectors. In 2022, Merck KGaA generated sales of €22.2 billion in 66 countries. The company, founded in 1668, is committed to scientific exploration and responsible entrepreneurship and remains majority-owned by the founding family. For more information, visit www.emdgroup.com.
Stay updated with MilliporeSigma on Twitter (@MilliporeSigma), Facebook (@MilliporeSigma), and LinkedIn. News releases from Merck KGaA are distributed via email and available on the EMD Group website. Residents of the U.S. or Canada can subscribe to online services at www.emdgroup.com/subscribe to tailor their subscriptions based on geographic location and preferences.
.jpg)
Comments
Post a Comment